Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course
ranging from localized or spontaneously regressing to widely metastatic disease …

Risk-based treatment approaches for neuroblastoma have been ongoing for decades.
However, the criteria used to define risk in various institutional and cooperative groups were …

Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-
clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study …

There is an urgent need to identify novel therapies for childhood cancers. Neuroblastoma is
the most common pediatric solid tumor, and accounts for~ 15% of childhood cancer‐related …

All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …

ABSTRACT A vast array of oncogenic variants has been identified for anaplastic lymphoma
kinase (ALK). Therefore, there is a need to better understand the role of ALK in cancer …

The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many
cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer …

Background Various human cancers have ALK gene translocations, amplifications, or
oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic …

Genetic studies have established anaplastic lymphoma kinase (ALK), a cell surface receptor
tyrosine kinase, as a tractable molecular target in neuroblastoma. We describe …

Neuroblastoma (NB), the most common extracranial tumor of childhood, is a cancer of
primordial neural crest cells that give rise to sympathetic neural ganglia and adrenal …